24/7 Market News Snapshot 17 October, 2024 – Amicus Therapeutics, Inc (NASDAQ:FOLD)

October 17, 2024

DENVER, Colo., 17 October, 2024 (247marketnews.com) – (NASDAQ:FOLD) are discussed in this article.
Amicus Therapeutics, Inc. (FOLD) has demonstrated strong market activity with its stock opening at $10.82 and climbing to $11.784, reflecting a notable increase of 12.23% since the previous session’s close at $10.50. This surge, accompanied by a trading volume of 3.58 million shares, signifies heightened investor interest and positive market sentiment. Analysts suggest that this upward momentum may stem from favorable news, possibly related to the company’s recent developments.

In a significant strategic move, Amicus has announced a License Agreement with Teva Pharmaceuticals, aimed at advancing therapies for rare diseases. This agreement effectively resolves existing patent litigation surrounding Teva’s Abbreviated New Drug Application for a generic version of GALAFOLD® (migalastat) 123mg capsules. As per the terms, Teva will be permitted to market its generic variant in the United States beginning January 30, 2037, contingent upon FDA approvals and standard conditions typically found in such agreements.

The conclusion of litigation with Teva allows Amicus to streamline operations and focus on future growth, although it continues legal proceedings against Aurobindo, the remaining defendant. The License Agreement will be subject to regulatory review and requires submission to the U.S. Federal Trade Commission and the Department of Justice, underscoring compliance with legal standards.

Amicus Therapeutics is steadfast in its mission to provide innovative treatments for rare diseases, focusing on developing high-quality medicines that cater to patient needs. The company remains committed to enhancing healthcare solutions and ensuring transparency, with further updates anticipated as they progress.

Related news for (FOLD)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.